Abstract: Disclosed is a method of distinguishing type III hyperlipidemia in the WHO-classified hyperlipidemia types (hereinafter referred to as type III) from other types of hyperlipidemia, which is a simpler method and has a higher diagnostic efficiency than conventional methods. The method of assisting the determination of type III hyperlipidemia includes the steps of: measuring the apoB-48 value, TG value and LDL-C value in a blood sample isolated from a living body; and calculating a ratio of the apoB-48 value divided by the TG value and a ratio of the apoB-48 value divided by the LDL-C value. In cases where both the ratio of the apoB-48 value divided by the TG value and the ratio of the apoB-48 value divided by the LDL-C value are higher than the respective cut-off values, it indicates that the living body is likely to have type III hyperlipidemia.

Abstract: The present invention relates to an inhibitor capable of increasing accuracy of the reaction in hybridization, and inhibiting nonspecific hybridization, a clinical diagnostic reagent, and a method of clinical analysis whereby nonspecific hybridization in clinical analysis is inhibited, and a target nucleic substance is detected easily with high accuracy. The inhibitor and the clinical diagnostic reagent contains polymer (H) having a nonspecific hybridization inhibitory action. The polymer has in its molecule at least one of carboxyl and sulfone groups, and phosphorylcholine-like groups, and has a weight average molecular weight of 1000 to 5000000. The method of clinical analysis includes contacting a sample with a test agent capable of hybridizing with a specific nucleic substance in the presence of the inhibitor.

Abstract: Disclosed are an immunoassay device which comprises a labeled substance dotting portion and a specimen dotting portion provided thereon, and an immunoassay method using the device.

Abstract: The present invention relates to an inhibitor capable of increasing accuracy of the reaction in hybridization, and inhibiting nonspecific hybridization, a clinical diagnostic reagent, and a method of clinical analysis whereby nonspecific hybridization in clinical analysis is inhibited, and a target nucleic substance is detected easily with high accuracy. The inhibitor and the clinical diagnostic reagent contains polymer (H) having a nonspecific hybridization inhibitory action. The polymer has in its molecule at least one of carboxyl and sulfone groups, and phosphorylcholine-like groups, and has a weight average molecular weight of 1000 to 5000000. The method of clinical analysis includes contacting a sample with a test agent capable of hybridizing with a specific nucleic substance in the presence of the inhibitor.

Abstract: Disclosed are an immunoassay device which comprises a labeled substance dotting portion and a specimen dotting portion provided thereon, and an immunoassay method using the device.

Abstract: Disclosed are an immunoassay device which comprises a labeled substance dotting portion and a specimen dotting portion provided thereon, and an immunoassay method using the device.

Abstract: Disclosed are an immunoassay device which comprises a labeled substance dotting portion and a specimen dotting portion provided thereon, and an immunoassay method using the device.

Abstract: An enzyme-labeled immunoassay is performed by the steps of allowing a test sample to react with an enzyme-labeled reagent, allowing a substrate to react with the enzyme to form a signal, and immobilising the enzyme-labeled reagent, with the prevention of a further signal formation from a predetermined time on after the immobilisation of the enzyme-labeled reagent, using an enzyme inhibitor.

Abstract: An enzyme-labeled immunoassay is performed by the steps of allowing a test sample to react with an enzyme-labeled reagent, allowing a substrate to react with the enzyme to form a signal, and immobilising the enzyme-labeled reagent, with the prevention of a further signal formation from a predetermined time on after the immobilisation of the enzyme-labeled reagent, using an enzyme inhibitor.

Abstract: There are disclosed a magnetic particle for an immunoassay method, which comprises a core and a coating layer formed on the surface of the core wherein said core comprises an organic polymer matrix and said coating layer comprises a mixed crystal ferrite represented by the formula:M.sub.x Fe.sub.(3-x) O.sub.4wherein M represents at least one metal selected from the group consisting of Mn, Ni, Zn, Co, Cu, Mg, Sn, Ca and Cd, and x is a number satisfying the relation: 0<x<3,and an antigen or an antibody is bound onto the surface of the coating layer and wherein said particle has a particle size of 0.03 to 10 .mu.m, and an immunoassay method using the same.